RANCHO SANTA MARGARITA, Calif., Jan. 22, 2003 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) announces that its first product, Histo-RECAF(TM) has been classified by the FDA as a Class I device under Regulation Number 864.1850, Code HZJ owned by BioCurex (FDA number 9046509). Thus, the product is now available as a "Staining test for AFP receptors (a.k.a. RECAF) in tissues" for sale to pathology laboratories across the USA (FDA text available at http://www.biocurex.com/fda )
Dr. Ricardo Moro, President of BioCurex commented: "We are very excited by this ruling since it will allow us to start commercializing Histo-RECAF(TM) in thousands of laboratories in the USA. Also, the FDA ruling and the previously announced notice of allowance by the U.S. Patent office are the two elements required for licensing this technology to other biopharmaceutical companies."
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAF(TM) kits provide proof of concept for the RECAF technology. Detailed information about BioCurex may be obtained from their Website at http://www.biocurex.com.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.